by | Jan 22, 2025 | Lupus Foundation of America, News & Events
Long-term use of glucocorticoids (GCs) for the treatment of lupus is very common, however, it has also been associated with side effects like high blood pressure, diabetes, infection, and osteoporosis. A new study found that low or absent disease activity,...
by | Jan 17, 2025 | Lupus Foundation of America
Living with lupus can significantly affect your mental health. This January we are honoring Mental Wellness Month by exploring the intersection of lupus and mental health with a four-part series of blog posts published every Friday. More than half of people with lupus...
by | Jan 14, 2025 | Lupus Foundation of America, News & Events
Neutropenia, a condition characterized by low neutrophil levels, is common in individuals with systemic lupus erythematosus (SLE) and can lead to severe infections. A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a...
by | Jan 14, 2025 | Lupus Foundation of America, News & Events
Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker assays designed to improve the detection of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The new biomarker tests will be...
by | Jan 14, 2025 | Lupus Foundation of America, News & Events
The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started. This open label, multicenter study will assess a single infusion of CB-010 in adults with LN, including those with extrarenal lupus (ERL,...
by | Jan 14, 2025 | Lupus Foundation of America, News & Events
The Phase 1 GALLOP study evaluating investigational therapy, CB-010, for treatment of lupus nephritis (LN) has officially started. This open label, multicenter study will assess a single infusion of CB-010 in adults with LN, including those with extrarenal lupus (ERL,...
